Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$455M Buy
2,089,885
+438,228
+27% +$97.2M 0.19% 93
2025
Q4
$377M Sell
1,651,657
-1,062,621
-39% -$242M 0.17% 100
2025
Q3
$628M Sell
2,714,278
-581,584
-18% -$118M 0.28% 51
2025
Q2
$612M Buy
3,295,862
+95,891
+3% +$17.8M 0.3% 56
2025
Q1
$670M Buy
3,199,971
+753,198
+31% +$146M 0.34% 40
2024
Q4
$435M Buy
2,446,773
+378,359
+18% +$69.6M 0.26% 65
2024
Q3
$408M Sell
2,068,414
-303,143
-13% -$56.6M 0.24% 72
2024
Q2
$407M Buy
2,371,557
+277,449
+13% +$46M 0.26% 67
2024
Q1
$381M Sell
2,094,108
-205,907
-9% -$35.5M 0.25% 64
2023
Q4
$356M Sell
2,300,015
-624,646
-21% -$91.1M 0.25% 63
2023
Q3
$436M Sell
2,924,661
-443,329
-13% -$65.1M 0.33% 42
2023
Q2
$454M Buy
3,367,990
+951,771
+39% +$140M 0.3% 44
2023
Q1
$385M Sell
2,416,219
-758,551
-24% -$116M 0.27% 52
2022
Q4
$513M Buy
3,174,770
+398,836
+14% +$61.2M 0.41% 31
2022
Q3
$373M Buy
2,775,934
+141,461
+5% +$20.3M 0.27% 56
2022
Q2
$403M Buy
2,634,473
+69,093
+3% +$10.6M 0.3% 45
2022
Q1
$416M Buy
2,565,380
+118,156
+5% +$17.2M 0.25% 58
2021
Q4
$331M Sell
2,447,224
-281,373
-10% -$33.2M 0.18% 95
2021
Q3
$294M Sell
2,728,597
-125,277
-4% -$14.3M 0.17% 99
2021
Q2
$321M Sell
2,853,874
-418,867
-13% -$47.2M 0.19% 89
2021
Q1
$354M Buy
3,272,741
+255,207
+8% +$27.3M 0.23% 80
2020
Q4
$323M Buy
3,017,534
+245,368
+9% +$23.6M 0.19% 90
2020
Q3
$243M Buy
2,772,166
+199,268
+8% +$18.8M 0.16% 100
2020
Q2
$253M Sell
2,572,898
-2,446,157
-49% -$215M 0.2% 81
2020
Q1
$382M Buy
5,019,055
+483,669
+11% +$41.2M 0.35% 44
2019
Q4
$402M Buy
4,535,386
+1,418,077
+45% +$118M 0.29% 52
2019
Q3
$236M Buy
3,117,309
+1,763,534
+130% +$121M 0.19% 90
2019
Q2
$98.4M Buy
1,353,775
+222,099
+20% +$17.5M 0.08% 236
2019
Q1
$91.2M Buy
1,131,676
+442,120
+64% +$36.2M 0.09% 210
2018
Q4
$63.6M Sell
689,556
-4,500
-0.6% -$396K 0.06% 307
2018
Q3
$65.6M Buy
694,056
+6,187
+0.9% +$587K 0.06% 298
2018
Q2
$63.7M Sell
687,869
-397,180
-37% -$38.8M 0.06% 284
2018
Q1
$103M Buy
1,085,049
+142,038
+15% +$15.6M 0.08% 185
2017
Q4
$91.2M Sell
943,011
-414,739
-31% -$39.1M 0.07% 240
2017
Q3
$121M Buy
1,357,750
+183,195
+16% +$13.9M 0.1% 159
2017
Q2
$85.2M Buy
1,174,555
+344,444
+41% +$23.2M 0.08% 197
2017
Q1
$54.1M Sell
830,111
-159,857
-16% -$10.1M 0.05% 334
2016
Q4
$62M Buy
989,968
+232,151
+31% +$14.2M 0.06% 318
2016
Q3
$47.8M Sell
757,817
-347,094
-31% -$22.5M 0.04% 357
2016
Q2
$68.4M Buy
1,104,911
+455,228
+70% +$27.7M 0.07% 268
2016
Q1
$37.1M Buy
649,683
+41,885
+7% +$2.33M 0.04% 377
2015
Q4
$36M Sell
607,798
-32,735
-5% -$1.89M 0.04% 474
2015
Q3
$34.9M Sell
640,533
-2,123,442
-77% -$138M 0.03% 462
2015
Q2
$186M Buy
2,763,975
+1,138,433
+70% +$74.3M 0.16% 84
2015
Q1
$95.2M Buy
1,625,542
+311,997
+24% +$18.8M 0.09% 192
2014
Q4
$86M Buy
1,313,545
+997,615
+316% +$62.9M 0.08% 250
2014
Q3
$18.2M Sell
315,930
-477,219
-60% -$26.5M 0.02% 862
2014
Q2
$44.8M Buy
793,149
+344,411
+77% +$18.1M 0.04% 395
2014
Q1
$23.1M Sell
448,738
-268,913
-37% -$13.6M 0.02% 637
2013
Q4
$37.9M Sell
717,651
-894,125
-55% -$43.9M 0.03% 477
2013
Q3
$72.1M Sell
1,611,776
-292,969
-15% -$13M 0.07% 257
2013
Q2
$78.7M Buy
+1,904,745
New +$83.3M 0.08% 197

Other funds holding ABBV

Citigroup's ABBV Position: Q1 2026 in Review

Citigroup increased its AbbVie (ABBV) stake by 27% in Q1 2026, buying an estimated $97.2M and bringing the position to 2,089,885 shares worth $455M. The position accounts for 0.19% of the portfolio, ranked #93.

Citigroup first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $670M in Q1 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Citigroup held 2,089,885 shares of AbbVie worth $455M as of Q1 2026.
  • Citigroup bought 438,228 AbbVie shares in Q1 2026, an estimated $97.2M.
  • AbbVie made up 0.19% of Citigroup's portfolio in Q1 2026, its #93 holding.
  • Citigroup first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's AbbVie position peaked at $670M in Q1 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.